Profile: DCE MRI Quantification

Version 1.0
Reviewed Draft (Public Comments Addressed)
July 1, 2012

Table of Contents

I. Executive Summary

The RSNA QIBA Dynamic-Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) Technical Committee is composed of scientists representing the imaging device manufacturers, image analysis laboratories, biopharmaceutical industry, academia, government research organizations, and professional societies, among others. All QIBA work is considered to be pre-competitive. The goal of the DCE-MRI committee is to define basic standards for DCE-MRI measurements and quality control that enable consistent, reliable and fit-for-purpose quantitative transfer constant (K^{trans})[1] and blood-normalized initial-area-under-the-gadolinium-concentration curve ($IAUGC_{BN}$)[2] results across imaging platforms (at 1.5 tesla (1.5 T)), clinical sites, and time.

This effort is motivated by the emergence of DCE-MRI as a method with potential to provide predictive, prognostic and/or pharmacodynamic response biomarkers for cancer [3-11]. Remarkably, the results demonstrating this potential have been obtained despite considerable variation in the methods used for acquisition and analysis of the DCE-MRI data. This suggests there are substantial physiological differences (i.e., benign vs. malignant or non-responsive vs. responsive tumors) underlying these observations. Thus, there appears to be a promising future for use of DCE-MRI for both clinical research and in routine clinical practice. However, in order to fulfill this promise it is essential that common quantitative endpoints are used and that results are independent of imaging platforms, clinical sites, and time.

For the application of DCE-MRI in the development of anti-angiogenic and anti-vascular therapies, there is a consensus [12] on which quantitative endpoints should be employed: K^{trans} and $IAUGC_{BN}$. Hence, the initial focus of the DCE-MRI committee is on these biomarkers. Although there have been general recommendations on how to standardize DCE-MRI methodology[12, 13], there are no guidelines sufficient to ensure consistent, reliable and fit-for-purpose quantitative DCE-MRI results across imaging platforms, clinical sites, and time. Hence, in this profile, basic standards for site and scanner qualification, subject preparation, contrast agent administration, imaging procedure, image post-processing, image analysis, image interpretation, data archiving and quality control are defined to provide that guidance.

Summary of Clinical Trial Usage

This technique offers a robust, reproducible measure of microvascular parameters associated with human cancers based on kinetic modeling of dynamic MRI data sets. The rigor and details surrounding these data are described throughout the text of this document in various sub-sections.

II. Clinical Context and Claims

One application of DCE-MRI where considerable effort has been focused on quantitative endpoints is its use to provide pharmacodynamic biomarkers for the development of novel therapeutic (in specific anti-angiogenic) agents targeting the tumor blood supply [4, 9, 14-26]. A growing understanding of the underlying molecular pathways active in cancer has led to the development of novel therapies targeting VEGFR, EGFR-tk, PI3K, mTOR, Akt and other pathways. Unlike the conventional cytotoxic chemotherapeutic agents, many of these molecularly-targeted agents are cytostatic, causing inhibition of tumor growth rather than tumor regression. One example is anti-angiogenesis agents, which are presumed to act through altering tumor vasculature and reducing tumor blood flow and/or permeability. In this context, conventional endpoints, like tumor shrinkage as applied through the Response Evaluation Criteria in Solid Tumors (RECIST) system,

may not be the most effective means to measure therapeutic responses. Other functional MR imaging acquisition and analysis applications (e.g. BOLD, R_2* perfusion) also yield several important candidate imaging biomarkers that can predict and monitor targeted treatment response and can document pharmacodynamic response. However, these are not within the scope of this document. DCE-MRI represents an MRI-based method to assess the tumor microvascular environment by tracking the kinetics of a low-molecular-weight contrast agent intravenously administered to patients.

The emerging importance of angiogenesis as a cancer therapy target makes assays of vascularity important to clinical research and future clinical practice related to targeted cancer therapy. There are multiple literature reports of the application of DCE-MRI to predict and detect changes associated with angiogenesis targeted therapy [4, 9, 15, 17, 19, 20, 24, 25] . Further, there is interest in the application of quantitative DCE-MRI to characterize enhancing lesions as malignant in several organ systems, including breast and prostate.

In this context, K^{trans} and $IAUGC_{BN}$ can provide evidence of the desired physiologic impact of these agents in Phase 1 clinical trials. For some agents, e.g., VEGFR-targeted agents, evidence of substantially reduced K^{trans} and $IAUGC_{BN}$ is necessary, but not sufficient, for a significant reduction in tumor size [16, 17] . For other agents, e.g., vascular-targeted agents, evidence of a substantial vascular effect may not be associated with a reduction in tumor size [9], but is still essential for effective combination with other anti-cancer agents. In either case, lack of a substantial vascular effect indicates a more potent agent is needed, while evidence for a substantial vascular effect indicates further development is appropriate.

Utilities and Endpoints for Clinical Trials

DCE-MRI is currently not the standard of care in many centers conducting clinical trials in oncology. Since these centers often do not have expertise in DCE-MRI and more than one center is typically involved, therefore effort and rigor are required to ensure consistent, reliable and fit-for-purpose quantitative DCE-MRI results. Hence, the guidelines provided in this profile will ensure that not only are the relative changes induced by treatment informative, but that absolute changes can be compared across these studies.

Claim:

Quantitative microvascular properties, specifically transfer constant (K^{trans}) and blood-normalized initial-area-under-the-gadolinium-concentration curve ($IAUGC_{BN}$), can be measured from DCE-MRI data obtained at 1.5T using low-molecular-weight extracellular gadolinium-based contrast agents with a 20% within-subject coefficient of variation for solid tumors at least 2 cm in diameter.[*]

Profile specified for use with: **patients with malignancy**, for the following indicated biology**: primary or metastatic**, and to serve the following purpose: **therapeutic response**.

[*] a 20% within-subject coefficient of variation is based on a conservative estimate from the peer-reviewed literature. In general, this suggests that a change of approximately 40% is required in a single subject to be considered significant.

III. Profile Details

1. Subject Handling

1.1 Subject Scheduling

Subject Selection Criteria related to Imaging

- Local policies for contraindications for absolute MRI safety should be followed. Definition of relative and/or absolute contraindications to MRI is not within the scope of this document.

- Lesions that are selected for DCE-MRI analysis should not be within 10 cm of metal prostheses, e.g., spinal hardware, hip prostheses, metallic surgical staples, etc.

- Patient selection criteria may be guided by the Eastern Cooperative Oncology Group (ECOG) status (See Appendix B for full description of ECOG performance status). Specifically, patients meeting ECOG status >= 2 may not be eligible for participation in the study because, historically, this patient profile has shown poor ability to meet the demands of the examination.

- The QIBA DCE-MRI committee acknowledges that there are potential and relative contraindications to MRI in patients suffering from claustrophobia. Methods for minimizing anxiety and/or discomfort are at the discretion of the physician caring for the patient.

- The QIBA DCE-MRI committee acknowledges that there are potential risks associated with the use of gadolinium-based contrast media. The default recommendations for intravenous contrast that follow assume there are no known contraindications in a particular patient other than the possibility of an allergic reaction to the gadolinium contrast agent. The committee assumes that local standards for good clinical practices (GCP) will be substituted for the default in cases where there are known risks.

- Recent FDA guidelines (http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm#aprooved), outline the safety concerns associated with using gadolinium-based contrast agents in patients with impaired renal function. The DCE-MRI committee echoes these recommendations and advises reference to these standards when choosing patients in order to determine eligibility for entry into a DCE-MRI clinical trial.

- Although the vascular half-life of the gadolinium contrast agents addressed by the Profile is approximately 90 min, it is strongly recommended that patients should not have received ANY gadolinium-based contrast agent within 24 hours before a DCE-MRI procedure as some residual contrast agent may remain in the lesion(s) of interest and the impact of such residual contrast agent on the within-patient coefficient of variation is unknown.

1.1.1. Timing of Imaging Tests within the Treatment Calendar

The DCE-MRI Technical Committee believes that all baseline evaluations should ideally be within 14 days. Otherwise the resulting functional tumor characterization may not reflect the status of the tumor prior to initiation of therapy. The interval between follow-up scans within patients may be determined by current standards for GCP or the rationale driving a clinical trial of a new treatment

1.1.2. Timing Relative to confounding Activities (to minimize effect of those Activities)

The presence of susceptibility artifacts and, possibly, mass-effect from hemorrhage and/or air related to recent biopsy may potentially affect the quantitative DCE-MRI parameters. If practical, it is recommended that DCE-MRI examinations should not be performed within 14 days after biopsy of lesions of interest. If this amount of delay is impractical, excluding hemorrhagic portions of lesions from the image analysis is strongly recommended.

1.2. Subject Preparation

There are no specific patient preparation procedures for the MRI scans described in this protocol. There are specifications for other procedures that might be acquired contemporaneously, such as requirements for fasting prior to FDG-PET scans or the administration of oral contrast for abdominal CT. Timing of those procedures may be followed as indicated without adverse impact on these guidelines

1.2.1. Prior to Arrival

The local standard of care for acquiring MRI scans may be followed. For example, patients may be advised to wear comfortable clothing, leave jewelry at home, etc.

1.2.2. Upon Arrival

Staff shall prepare the patient according to the local standard of care, (including, e.g., removal of all metal objects and electronic devices). Patients should be comfortably positioned, in appropriate attire to minimize patient motion and stress (which might affect the imaging results) and any unnecessary patient discomfort.

1.2.3 Preparation for Exam

Beyond a clear, simple language description of the image acquisition procedure, no exam preparation is specified beyond the local standard of care for MRI with contrast.

1.3. Imaging-related Substance Preparation and Administration

1.3.1. Substance Description and Purpose

The literature which supports this Profile Claim, is based on the utilization of an extracellular gadolinium-based contrast agent. Although it is known that there is a small degree of protein binding associated with many commercially-available extracellular gadolinium contrast agents, [27], these are comparable amongst the various vendors. Contrast agents with fundamentally different degrees of protein binding, (e.g., Gadobenate and Gadofosveset) are not addressed by this profile. The committee therefore recommends using a classical extracellular-based gadolinium-based contrast agent.

1.3.2. Dose Calculation and/or Schedule

Total contrast agent dose depending on body weight and renal function:

- Before DCE-MRI the patient's renal creatinine clearance should be obtained, and estimated glomerular filtration rate (eGFR) determined through well-known and adopted formulas. [28]

- Routine dose of the Gadolinium contrast agent should be 0.1 mmol/kg.
- The decision whether to administer total contrast dosage will be based on GCP and the policies adopted at the institution performing the examination. However, the same body-weight-adapted contrast agent concentration should be used for repeat studies, and in case of acute renal insufficiency and/or renal failure at follow-up a later imaging time point or patient exclusion should be discussed.

1.3.3. Timing, Subject Activity Level, and Factors Relevant to Initiation of Image Data Acquisition

Contrast injection should occur after the following imaging sequences have been acquired (See Section 6):

- Anatomic imaging for localizing tumors
- Variable flip angle imaging for native tissue (pre-gadolinium injection) T_1 map calculation

Contrast injection should occur after at least 5 baseline acquisitions from the imaging volume have been acquired.

1.3.4. Administration Route

It has been demonstrated in studies of CT arteriography, contrast-enhanced CT, and contrast-enhanced MR arteriography that left arm injections lead to reflux of contrast agent into venous structures [29-31]. It stands to reason that inconsistencies in the arm that is injected could, therefore, lead to variability in the shape of the VIF, further exaggerating the potential inaccuracy of an assumed input function. Therefore, it is recommended that each subject should have an intravenous catheter (ideally no smaller than 20 gauge (0.8mm inner diameter)), which should be ideally placed in the right antecubital fossa. Injection through a port-a-catheter or permanent indwelling catheter is not recommended. What is critical is that the same injection site and catheter size be used for repeat studies, if at all possible.

1.3.5. Rate, Delay and Related Parameters / Apparatus

Contrast agent and normal saline flush should be administered in a dynamic fashion with an MR-compatible power injector.

- At baseline and at each subsequent time-point in any longitudinal study, the same dose of contrast (in mmol/kg) and rate of contrast administration should be performed.
- The rate of administration should be rapid enough to ensure adequate first-pass bolus arterial concentration of the contrast agent (generally 2-4 ml/sec)
- The contrast agent should be flushed with 20 to 30 ml of normal saline, which should be injected at the same rate as the contrast agent.

1.3.6. Required Visualization / Monitoring, if any

No particular visualization or monitoring is specified beyond the local standard of care for MRI with contrast.

2. Imaging Procedure

This section describes the imaging protocols and procedure for conducting a DCE-MRI exam. Suitable localizer (scout) images must be collected at the start of exam and used to confirm correct coil placement as well as selection of appropriate region to image. This will be followed by routine non-contrast agent-enhanced sequences to delineate the number, location, and limits of tumor extension. Exact protocols for these imaging sequences may be determined by the local imaging norms, e.g.,:

- **Localizer**
- **Anatomic sequences T_1, T_2 weighted imaging**
- **Variable Flip angle (VFA) T_1 weighted imaging (T_1 mapping)**
- **3D Gradient echo volumetric imaging (dynamic imaging)**
- **Anatomic, post-contrast T_1 weighted sequences**

2.1. Required Characteristics of Resulting Data

The DCE-MRI portion of the exam will consist of two components, both acquired using the same 3D fast spoiled gradient recalled echo sequence, or equivalent, and scan locations:

(a) A variable flip angle (VFA) series, for pre-contrast agent native tissue T_1 mapping.

- Ensure TR and TE values stay constant for all flip angles,
- Ensure that the machine gain settings are not reset automatically (using automated pre-scan features) between each flip angle acquisition so that system gain settings are identical for each flip angle acquisition.
- Flip angles: The range of numbers of flip angles supported in the literature varies from 2-7.
- Number of signal averages (NSA or NEX) ≥ 2.
- Fat saturation if used may alter baseline T_1 values and therefore should be consistently used throughout the examination.
- The pulse sequence and coils used for T_1 calculation should be the same used for the DCE-MRI Protocol (see 2.1 b).

(b). DCE-MRI Protocol: Pulse Sequence:

- ***Pulse Sequence:*** 3D fast spoiled gradient recalled echo or equivalent
- ***Coils:*** Transmit: Body coil; Receive: Body coil or phased array receive coil dependent on which body part is being studied, e.g., torso (pelvic applications), breast coil (breast applications)
- Parallel imaging options are not recommended due to vendor-specific implementations of such techniques and the fact that the effects of such techniques on within-patient coefficients of variation in Ktrans and $IAUGC_{BN}$ have not been evaluated.
- No magnetization preparation schemes are specifically addressed by this Profile, including the use of saturation pulses for fat suppression. The use of such pulses may impact the within-subject coefficient of variation and should be investigated prior to use.
- ***Imaging plane*** **-** The acquisition plane should include the lesion of interest and a **feeding vessel with in-plane flow** in order to capture a **vascular input function (VIF)**. In addition, the choice of the acquisition plane should be made, where possible, to mitigate the effects of lesion motion, e.g., coronal-oblique plane for a liver lesion.
- **Frequency encoding direction:** The frequency encoding direction should be adjusted so as to

minimize motion artifact. This decision will be based on the location of the tumor being interrogated and its relationship to moving structures.

Parameter	Compliance Levels (for DCE acquisitions)	
TE	Acceptable	2.0-2.5ms
	Target	1.5-2.0ms
	Ideal	<1.5ms
TR	Acceptable	5-7ms
	Target	3-5ms
	Ideal	< 3ms

*Note: The table above specifically addresses the DCE-MRI acquisition. The choices of TE and TR might be modified slightly for the pre-gadolinium administration R1 measurements. For example, the TR may be lengthened for more optimal R1 quantification.

- **Temporal resolution:** The temporal resolution should be less than 10 sec.

- **Flip angles:** Flip angles ranging from 25-35 degrees are recommended in order to minimize saturation effects. Smaller flip angles will lead to potential saturation of the signal intensity vs. gadolinium concentration, particularly in vessels. It should be noted that SAR limits may affect the maximum allowable flip angle and, of course, such limits may be affected by the patient's weight and, for some scanners, weight and height. The technologist should use the maximal allowed flip angle when SAR limitations occur. In addition, the number of imaging sections may be reduced, if practical, to help mitigate the SAR limitations while maintaining a flip angle in the desired range stated above.

- **Receiver Bandwidth**: Greater or equal to ±31.25 kHz (or ~250 Hz/pixel)

- **Field of View (FOV) and Partial Fourier ("fractional echo" and/or reduced phase-encoding FOV) as needed to meet temporal resolution requirements**

- **Number of Slices:** Acceptable: ≥10 prior to zero fill. Ideal: as many as possible while maintaining ideal temporal resolution.

- **Slice thickness**: *Ideal*: <5 mm, *Target*: 5.1-6 mm, *Acceptable*: 6.1-8 mm

- **Matrix:** 256 x 160 (before applying rectangular FOV) – in order to meet 1-2mm in-plane spatial resolution

- **Number of acquisitions (phases):** Sufficient to allow acquisition of at least 5 minutes of post injection data plus at least 5 phases acquired before contrast agent injection (baseline images).

- **Digitized bit depth:** The maximum dynamic range should be utilized, e.g., "extended dynamic range" or equivalent.

2.1.1. Data Content

All imaging data should be stored in DICOM format.

2.1.2. Data Structure

All variable flip angle (VFA) data should be clearly labeled as individual series, one per flip angle, or contained in a single series with the data order clearly defined.

All DCE-MRI data should be contained in a single series.

2.1.3. Data Quality

A quality review, confirming that all imaging parameters were correct, data structure is correct, etc., before the data are submitted for analysis.

2.2. Imaging Data Acquisition

2.2.1. Subject Positioning

(a) Patient and coil positioning:

- When the general location of the target tumor(s) is known prior to DCE-MRI, for example glioma or local breast cancer evaluation, the patient set up for the MRI should be based on standard operating procedures for patient positioning and coil placement for clinical MRI of that body part taking into account the total scan time (see below).

- When the subject under investigation may have uncertain tumor location(s), as is common in the setting of patients undergoing therapy for metastatic disease, it will often be necessary for the DCE-MRI study to be planned with reference to the most recent pre-DCE-MRI imaging (often a CT study). From this study, tumor burden and location should be assessed. Optimally, review of actual imaging by a radiologist involved in the DCE-MRI study planning should be made. At times, if such images are not available for direct review, review of imaging reports (CT, PET) detailing extent of disease is mandatory, both to confirm eligibility (presence of at least one "imageable" target lesion) and to identify the preferred anatomic regions for DCE-MRI (chest, abdomen, pelvis, extremity). Review of prior diagnostic imaging may also be helpful to confirm cystic or necrotic nature of certain lesions, assessments which may be challenging at the time of DCE-MRI planning based solely on T_1- and/or T_2-weighted image sets. When multiple potential target lesions are available, the location of the most suitable lesion(s) should be noted. The most suitable lesion will depend on size, location relative to areas of pulsatile or respiratory artifacts, and presence or

absence of necrosis or cystic areas.

- DCE-MRI subject should be placed appropriately in the scanner in order to best image the lesion of interest (e.g. supine for head/neck/thorax/abdomen/pelvis and prone within a breast coil for breast studies).

- When patient condition allows, placement of the arms over the head may avoid undesirable wrap artifact for temporally-optimized 3D spoiled gradient echo sequences used for chest and abdomen lesions. However, these positions often cannot be sustained by patients without excessive discomfort. In such cases, arms placed anteriorly over the chest or at the sides may be preferable. For larger patients, side-down arm positioning may require adjustment of the DCE-MRI imaging FOV to avoid undesirable wrap artifact. Appropriate coil placement per area of examination (head, neck, breast, extremity) is then done. For lesions in the chest, abdomen, or pelvis, a torso array coil is then placed in the area of target lesion(s). Ideally, both anterior and posterior coils are centered over the expected target lesion location.

- Tumor size and location on longitudinal studies should be considered in the design of an analysis scheme. Recall that the claims of this Profile are only applicable to lesions greater than or equal to 2cm. If the lesion is large in proportion to the volume imaged by DCE-MRI, precautions should be taken to maximize the possibility that the same portion of the lesion will be imaged on longitudinal studies. In general, this requires careful scan location set up on follow-up studies in order to match the same anatomic positions imaged in target organs on earlier studies (e.g. by saving of the planning screen shot). However, because of differences in patient angulation on follow-up studies the same anatomic locations may not be imaged on each study. In this case, an analysis scheme that discards image data from locations that are not included in the imaged volume (after end slice elimination) of all relevant studies is favored. This can be accomplished by registration of images obtained from the dynamic sequences of all studies (for example, images obtained by averaging all dynamic images obtained at the same location) to high-resolution anatomic images obtained (for example) at the initial time point.

- Tumors that are predominantly solid without significant necrosis or cystic characteristics would be considered the ideal choice of tumor for analysis. Tumors with extensive hemorrhage, or completely cystic or necrotic lesions are considered non-ideal and should be excluded from consideration.

- Tumor locations should be chosen to minimize the effects of excessive respiratory or pulsatile motion. Ideally, these would include the soft tissues of the extremities, posterior chest wall, retroperitoneum and abdomen. Although areas with some respiratory motion (e.g. kidneys, adrenal glands, retroperitoneum, lateral chest wall, pancreas, lung apices, neck) are considered acceptable, lesions within the hila, pericardium and lateral segment of the left lobe of the liver are not ideal because imaging of those areas will be significantly compromised secondary to respiratory motion.

2.2.2. Instructions to Subject During Acquisition

The patient will be instructed to relax and perform slow, steady breathing during the examination.

2.2.3. Timing/Triggers

All examinations will be performed in slow free-breathing state. Timing parameters for the bolus injection

of contrast agent will occur after the acquisition of no less than 5 baseline volume scans.

2.2.4. Model-specific Scan Parameters

Appendix D lists acquisition parameter values for specific scanner models/versions that can be expected to produce data meeting the requirements of Section 7.1.

2.3. Imaging Data Reconstruction

All imaging data reconstruction will be performed per vendor specification and will involve Fourier transformation of Cartesian data. No user-selected smoothing or other post-processing will be performed so as to insure the integrity of the data for image analysis.

2.3.1. Scanner-specific Instructions

Appendix D lists reconstruction parameter values for specific scanner models/versions that can be expected to produce data meeting the requirements of Section 7.2.

3. Image Post-processing

There are no specific image post-processing requirements in this Profile. No user-selected post-processing filters or image normalization methods should be used prior to data analysis as described in the next steps. If phased-array receiver coils are used, image combination and reconstruction should be according to standard manufacturer algorithms.

4. Parametric image formation

Analysis of DCE-MRI data is carried out in a series of distinct steps:

- Generate a native tissue T_1 map using the VFA data.
- When required, apply time-series motion correction to the dynamic data.
- Convert DCE-MRI signal intensity data, SI(t), to gadolinium concentration ([Gd](t)).
- Calculate a vascular input function.
- Identify the region or regions of interest in the dynamic data.
- Calculate the DCE-MRI imaging biomarker parameters, K^{trans} and $IAUGC_{BN}$.

Each of these steps is addressed in detail below.

4.1. Input Data to Be Used

Processed magnitude images will be utilized for image analysis for input into the steps described in the following sections

4.2. Methods to Be Used

(a) Generate a T_1 Map

The intent of this step is to provide a complete map of pre-contrast T_1 values for the imaged slab. These values will then be used in the signal formation model-based conversion of changes in signal intensity to gadolinium concentration. The slice locations, orientation and resolution of these images should be

prescribed identically to the dynamic series, and this series should be acquired immediately prior to the dynamic series. The output of this step is an image of T_1 values which can be co-registered to the dynamic series and used in subsequent calculations. The T_1 values at each voxel location are calculated as follows [1]:

1. Create a vector x containing the signal intensity at each flip angle divided by the tangent of the flip angle.
2. Create a vector y containing the signal intensity at each flip angle divided by the sine of the flip angle.
3. For the n-acquired flip angles create a set of points (x0,y0)… (xn,yn).
4. Fit a line with slope s to the set of points defined in Step 3.
5. $T_1 = -TR/\ln(s)$.

The use of non-linear curve fitting methods (for example, simplex or Levenberg-Marquard techniques) to extract T_1 from the signal intensities theoretically may be more robust to noise then the linearized solution presented above. Non-linear techniques may be used if they are validated using test images to perform no worse than the solution above in the expected range of T_1, equilibrium magnetization and noise of tumors and vessels to be imaged**.**

(b) Apply Motion Correction to the Dynamic Data

The intent of this step is to correct for patient motion that occurs between acquired phases of the dynamic data due to respiration, swallowing, and other involuntary movements. This step is not intended to correct ghosting artifacts that can occur along the phase encoding direction within a particular image due to patient motion during acquisition. These artifacts are more or less intractable unless the motion is regular and easily modeled, and are best addressed by adjusting the phase/frequency encoding scheme to minimize their impact on structures of interest. In general, simple rigid shift or affine-transform-based registration methods will not be adequate for this step, due to the fact that the movement in question is typically limited to specific regions within the image – for example, the liver in a coronal scan of the abdomen may move substantially with respiration while the bulk of the body remains relatively motionless. Fully deformable registration methods based on optical flow may provide good results in some cases [32, 33] . However, these methods will frequently fail for the phases immediately surrounding the contrast injection. Semi-automated registration in which a user identifies the target tumor and only information drawn from that region is used to generate phase to phase shifts provides an alternative approach. This allows rigid shift methods using mutual information [34], which tend to be more robust than optical flow methods, to be employed. Finally, registration may be carried out manually or using simple shift registration techniques [21]. Data corrupted with motion must be either corrected prior to analysis or discarded for subsequent pharmacokinetic analysis.

(c.) Convert SI(t) in the Dynamic Data to [Gd](t)

The intent of this step is to convert the arbitrary signal intensity units in the dynamic data into units of gadolinium concentration. This step should be applied after the regions of interest for analysis have been defined, but prior to the calculation of vascular parameters. Two methods for accomplishing this are defined below.

***Method A: Conversion Using a Signal Formation Model Gadolinium concentration at each image pixel is given by (eq** 1):*

$$C(t) = \left(\frac{1}{T_1(t)} - \frac{1}{T_{10}} \right) / R_{Gd} \qquad \text{Eq. 1}$$

Here T_{10} is the pre-contrast T_1 at that pixel, obtained as described above, and R_{Gd} is the relaxivity of Gd (obtained from contrast agent manufacturer's specifications).

$T_1(t)$ can be derived from the SPGR imaging equation (neglecting T_2* effects, assuming T2*>>>TE) and is given by the following expressions (eqs 2-4): Let

$$E_{10} = \exp(-TR/T_{10}) \qquad \text{Eq. 2}$$

$$B = \frac{1 - E_{10}}{1 - \cos\alpha * E_{10}} \qquad \text{Eq. 3}$$

$$A = B * SI(t) / SI(0) \qquad \text{Eq. 4}$$

where α is the flip angle, TR is the repetition time, and SI(t) and SI(0) are the signal intensities at time t and pre-contrast baseline respectively in the DCE-MRI sequence (eq 5). Then,

$$\frac{1}{T_1(t)} = \frac{-1}{TR} * \ln\left[\frac{1 - A}{1 - \cos\alpha * A} \right] \qquad \text{Eq. 5}$$

Method B: Conversion Using a Look-Up Table

This method is motivated by the concern that inaccuracies in T_1 mapping and/or co-registration of initial T_1 values to the dynamic data may introduce excessive variability into the final calculated parameters. If this method is used, it is not necessary to acquire the T_1 mapping data described above. This method assumes a high degree of response uniformity, and so may be limited in cases where phased array coils are used. In general it is recommended to use the inherent body coil for both transmit and receive when using this method. It should also be noted that the use of this method will introduce a uniform bias in the estimation of quantitative parameters which will impact absolute measurements, but will not affect quantification of change, for example from one exam to another. This method has been shown to yield better test-retest reproducibility than T_1-based quantification method. [14, 35]

This method requires that a phantom containing a range of concentrations of gadolinium and a range of baseline T_1 values (generally obtained via different concentrations of copper sulfate or a similar compound) is scanned using the dynamic protocol on each scanner that will be used for the study. Data from these phantoms can then be used to construct a look-up table relating baseline T_1, signal delta, and gadolinium concentration. In order to create this look-up table, a linear correlation is performed between the difference of signal intensity between that in a phantom concentration sample and a sample with no gadolinium concentration (used as x-axis values) and the nominal R_1 (1/ T_1) of the concentration sample. The resulting slope m then be used to estimate Gd concentration C using the equation C = m * [SI(t) - SI(0)], where SI(t) is the signal intensity in the dynamic data for a given time point t, and SI(0) is the signal intensity in the same location at baseline (before contrast agent injection).

(d) Calculate a Vascular input Function (VIF)

The intent of this step is to generate an accurate, patient-specific vascular input function (VIF) to serve as an input to the vascular model. One way to accomplish this is to have an analyst draw a manual ROI within

an artery, and use the mean enhancement curve within that ROI as the subject-specific VIF, as described by Vonken et al. [36]. It has been demonstrated previously that this method has significant variability associated with it [37], due primarily to the spatially- and temporally-varying flow artifacts found in major arteries. A better option is to make use of an automated search technique to generate a locally optimal VIF. Several methods of accomplishing this have been described. [38-40]

The signal for the vascular input function can then be converted into concentration using either Method A or B as described above.

In some cases, data-driven vascular input functions may be difficult to measure accurately due to anatomy, motion, flow effects, and T_2* effects. In these situations, alternative methods of using population-averaged vascular input functions[41-44] or reference-tissue-based vascular input functions [41-44] may be used. These methods in general lead to poorer characterization of subject-specific physiology and lead to poorer reproducibility [45].

(e) Calculate the Vascular Parameters

The intent of this step is to generate the parameter set which will be used to characterize the tissues of interest. Parameters will be calculated based on the standard Tofts model [39], which is derived from the Kety equations [46]. The vascular bed is modeled as a linear system, such that (eq 6):

$$C_t(t) = C_p(t) \otimes h(t) \qquad \text{Eq. 6}$$

with impulse response h(t) given by (eq 7):

$$h(t) = K^{trans} * \exp(-k_{ep}t) \qquad \text{Eq. 7}$$

where K^{trans} is the volume rate constant between blood plasma and extra-cellular extra-vascular space (EES) and k_{ep} is the rate constant between the EES and blood plasma. Given the tissue uptake curve $C_t(t)$ and the VIF $C_p(t)$, K^{trans} and k_{ep} are estimated using a gradient-descent energy minimization scheme, by using already established Levenberg-Marquardt or Minpack-1 curve fitting algorithms, both of which require adequate baseline sampling[47] . Delay correction should be performed to shift the VIF curve to match the arrival time of the tumor curve for each voxel prior to curve fitting.
A full parameter set will be calculated for each voxel within the defined tumor boundaries. Parameters may be reported out either as mean and median values per tumor or as histograms.
The baseline timepoint is defined as the timepoint immediately preceding the change in gadolinium concentration intensity. The blood normalized $IAUGC_{BN}$ is defined as the area under the concentration curve from the baseline timepoint up to 90 seconds post bolus arrival within the tumor, divided by the area under the vascular input function curve, up to 90 seconds post the baseline timepoint within the vessel.

4.4. Platform-specific Instructions

Appendix D lists image analysis parameter values for specific scanner models/versions that can be expected to produce data meeting the requirements of Section 5.

5. Parametric image analysis

Derivation of quantitative parameters characterizing the response associated with a lesion of interest from parameter maps is a multistep process, most, if not all, of which are being studied by on-going research. There are several choices that can be made at any of these steps, and the effect of these choices on the

validity of results and variability of parametric maps has not yet been fully characterized.

When multi-institutional trials are undertaken, a central site for analysis is highly recommended so as to reduce variability in analysis.

5.1. Input Data to Be Used

The input data that will be utilized will be in the form of concentration curves, and parametric maps of K^{trans} and $IAUGC_{BN}$ from which ROI analysis can be performed. One shortcoming of the 3D fast spoiled gradient recalled echo technique used to acquire the dynamic images is that initial and end slice locations give inaccurate results due to wraparound artifact and variability in excitation profile. The extent of this wraparound artifact is dependent on slice-oversampling and other vendor-specific techniques. Image analysis can begin by removing areas that are subjectively compromised by wraparound artifact. One method that can be used to determine which slices to discard is to closely examine the T_1 maps obtained at the initial and end slice locations. Marked non-physiologic overestimations of T_1 on initial and end slices are indicative of artifact.

5.2. Methods to Be Used

The following methodology for image interpretation of parametric maps should be performed in order to ensure completely reproducible and interpretable results.

(a) Tumor ROI Definition.

- The first step in the extraction of quantitative parameters (K^{trans} or $IAUGC_{BN}$) associated with a particular lesion is to segment this lesion from adjacent tissues. Which techniques of segmentation are ideal or even acceptable for a given application is the subject of on-going research, but it is clear that the segmentation techniques used must be tailored to the particular organ system being studied with DCE-MRI. The following guidelines are proposed:

- The committee does not recommend an analysis scheme where an operator defines a lesion by placing regions of interest directly on parameter maps as that will introduce bias into the results

- Less subjective results can be obtained by using correlative imaging to define the lesion. These correlative images may be obtained at the same imaging session but not directly related to the DCE-MRI images. (For example, a T_2-weighted image of an organ, which clearly delineates lesions and their boundaries, may be used.) Correlative images should be obtained in the same imaging plane as the DCE-MRI series, with similar FOV and spatial resolution, if feasible. In this scenario, a registration step will likely be required (see 9.2)

- An alternative approach, which may be helpful if the lesion is well delineated on contrast-enhanced T_1-weighted MRI, is to create summation images (images obtained by adding together images obtained on the dynamic series for each slice location). The average images can be used to segment the lesion on one or more slices, and because these segmentations are (in the absence of patient or organ motion) registered to the dynamic series, the segmentations can be used to directly extract lesion-based parameters from parametric

maps.

- Because of the presence of image noise on source images of the dynamic series, along with time-dependent changes in signal intensity which may blur or even obliterate the border between lesion and background tissue, analysis schemes in which lesions are segmented independently on each image of the dynamic series should be avoided where possible. In the case of moving organs, it may be necessary to segment the lesion of interest on early (preferably, before the arrival of the contrast bolus) or late dynamic images and estimate the position of the segmented lesion in intermediate time points.

- Although lesions can be segmented using manual techniques, several techniques are available that allow a semi-automated approach to be used. The training of operator or operators in performing segmentations should be documented, preferably with training sets.

(b) Registration of segmentations and parameter maps.

Unless the segmentations are derived from relatively motion-free or motion-corrected dynamic images (for example, summary images) image registration techniques may need to be used to place the segmentations and parameter maps into a single anatomic framework (see Section 4.2). The choice of registration technique to be used depends upon the organ system being imaged; the details of this are beyond the scope of this document. In performing registration techniques, either images aligned with the parametric maps or correlative images upon which the segmentation was performed are used as the target image for registration. The registered images are then interpolated from the source images. In interpolating parameter maps to match correlative images, tri-linear techniques are favored to avoid artifacts that may be associated with more advanced interpolation techniques.

(c.) Extraction of values for statistical comparison

To derive values for statistical comparison from K^{trans} or $IAUGC_{BN}$ parameter maps, median, mean and standard deviation of the pixel values should be calculated, and the median is considered the primary figure of merit. In a patient with multiple lesions due to metastatic disease, each lesion should be reported and tracked separately. In a patient with multiple lesions due to recurrent local tumor (for example, recurrent glioblastoma) per-patient figures of merit should be reported by aggregating the results of the multiple lesions.

(d) Choice of time point for segmentation.

As a rule, the K^{trans} or $IAUGC_{BN}$ at a given time point should be extracted using tumor ROIs segmented from the same imaging examination. However, in the situation where anti-angiogenic therapies are evaluated and post-therapy imaging is performed within 72 hours of initial treatment with the anti-angiogenic agent, it is acceptable to use a recent (within 1 week) pre-therapy time point to provide the segmentation used to define the lesion on the immediate post-therapy imaging session. In this case, it is presumed that changes in the appearance of lesions on the immediate post-therapy study are due to immediate decreases in permeability or blood flow rather than decrease in lesion volume.

In settings where analysis is performed retrospectively, all time points should be made available to the

reader simultaneously to allow for consistency in choice of tumor(s) for segmentation, and to ensure that similar regions of large tumors have been sampled and segmented. In the case of manual VIF segmentation, such workflow analyses also allow for greater standardization of the region of the aorta or other artery used in the analysis. In such settings, the reader should be blinded to the nature of each time point, so that inherent bias in tumor and/or VIF segmentation does not influence the results.

6. Archiving and Distribution of Data

Archiving and data distribution procedures are recommended so that all analysis results can be recomputed for verification and validation purposes. In addition to saving of all original images in DICOM formats, the following information must be archived along with the image data:

6.1. Post-Processed Data

- **VIF:** Detailed specification of the vascular input function selection. This may include a binary mask of pixels selected for arterial input function, or may consist of a tabulated text file containing RAS coordinates of the VIF pixel locations.

- **Registration:** Recorded parameters and user inputs required for image registration, if used. Time-series image registration may be used to align data spatially over time. Any parameters which control the performance of the registration algorithm (metric used, optimization parameters, user click-points/sub regions used for alignment, etc) must be stored in suitable format. It is preferable to save the registration transform parameters so that identical registration can be reproduced in a multi-center environment.

6.2. Analysis Results

All regions of interest where analysis is performed and statistics are computed should be saved. In addition, all computed maps (K^{trans} and $IAUGC_{BN}$), should be saved in DICOM and DICOM secondary capture modes. In the conversion to DICOM output, K^{trans} values should be reported in units of min^{-1} * 1000.

6.3. Interpretation Results

All interpretation of results should be saved for purposes of verification and audit.

7. Quality Control

The following section deals with all aspects of quality control in DCE-MRI studies. This includes selecting and qualifying an MRI imaging center, MRI personnel, and specific MRI scanners. In addition, the use of phantom imaging (prior to study initiation and ongoing) is discussed. Finally, post-image-acquisition quality assessment is detailed. Details of these processes will vary for investigator-initiated single-site studies versus sponsor-driven multi-site studies.

Mechanisms for appropriate patient and tumor selection, image acquisition, and post-processing are discussed throughout the document.

7.1. Selection of appropriate imaging centers for DCE-MRI studies

Typically sites are selected for DCE-MRI due to their competence in clinical oncology and access to a sufficiently large patient population under consideration. Sites must also be highly competent in clinical MRI techniques appropriate to the area(s) of anatomy to be imaged during the DCE-MRI study. In order to ensure high quality DCE-MRI results, it is essential to implement procedures that ensure quality assurance of the scanning equipment and reliable image acquisition methodology. These processes must be set-up at the outset, and followed throughout the duration of the study. A site "imaging capability assessment" prior to site selection is therefore a requirement for any DCE-MRI study. This will include assessment of:

- appropriate imaging equipment and quality control processes (see section 7.1.1)
- appropriate injector equipment and contrast media
- experienced MR technologists
- experienced MR radiologists
- experienced MR physicists or MR imaging scientiests
- procedures to assure imaging protocol compliance during the trial

7.1.1 DCE-MRI Acquisition Scanner

DCE-MRI studies as developed in this QIBA Profile require a 1.5 T MR scanner. The scanner software version should be identified and tracked across time, with updates and changes in scanner software noted during the course of a trial.

Proper coil maintenance must be performed to ensure adequate coil performance. It is beneficial to have alternate receiver coil systems available in the event that coil malfunction is identified prior to or during a DCE-MRI study.

The MRI scanner and receiver coils must undergo routine quality assurance and quality control processes (including preventive maintenance schedules) appropriate for clinical MRI applications. In addition, in order to assure adequate quantitative MR imaging results, additional quality control measures are required, as discussed below.

It is beneficial to identify and qualify more than one 1.5T MRI scanner at the site, if such are available for study use. This will ensure that if the primary MRI scanner is temporarily unavailable, the DCE-MRI study may proceed on a secondary scanner.

7.1.2 DCE-MRI Power Injector

A power injector is required for all DCE-MRI studies. The power injector needs to be properly serviced and calibrated.

7.1.3 MR Technologists or other Site Personnel performing DCE-MRI studies

MR technologists or other imaging expert(s) performing DCE-MRI procedures should be MR-certified according to local regulations or institutional requirements. These individuals should have prior experience in conducting dynamic contrast enhanced imaging. The personnel should also be experienced in clinical study related imaging and should be familiar with good clinical practices (GCP). Competence in the performance of DCE-MRI should never be limited to a single individual at the imaging center, as scheduled

and unplanned personnel absences are to be expected in the course of a DCE-MRI trial.

7.1.4 MR Radiologists or other anatomic experts

As tumor identification and selection is a critical component of the DCE-MRI study, sites performing DCE-MRI must have access to highly qualified MRI radiologists or other experts in MRI anatomic assessment. These individuals must be available during each DCE-MRI study to confirm adequate tumor selection and slab placement. In some settings, (e.g. brain tumors), it may be feasible for tumor identification and slab placement to be performed by the MR technologist, with oversight by a neuro-radiologist. In other cases (e.g. wide-spread metastatic disease in the chest, abdomen, or pelvis), it is accepted that a radiologist or other anatomic specialist must be available to identify tumor locations prior to contrast injection. It is expected that more than one anatomic specialist be available at a site performing the examination, should the primary anatomic specialists not be available for a given study.

7.1.5 Site compliance with protocol requirements

Imaging centers participating in DCE-MRI trials must adhere to accepted standards of quality control in imaging studies. This includes processes to identify patients, who are participants in research studies, personnel familiar with local IRB and other regulatory practices, proper understanding of source documentation, and reporting of protocol deviations and adverse events. Imaging centers must be able to document their compliance with DCE-MRI procedures in order to facilitate central quality control and auditing processes. Centers participating in multi-site trials must be familiar with protocol-directed methods for image transfer of HIPAA-compliant anonymized imaging data, properly annotated, to central analytic laboratories.

7.2 Site qualification process

7.2.1 Site readiness

Site readiness for DCE-MRI should be documented prior to the initiation of the DCE-MRI trial. In single-site studies initiated by in-house investigators, imaging procedures should be reviewed with the DCE-MRI team prior to study initiation. In multi-site studies, site readiness assessment can begin with a simple questionnaire completed as a pre-qualification step. A subsequent site visit prior to DCE-MRI study initiation is recommended. During the site visit, study-related imaging procedures and protocols are discussed. Ideally, all DCE-MRI scan parameters are reviewed and entered at the MR scanner at the time of the study visit. In some cases, initial phantom scanning can be performed during the site visit to familiarize local MR personnel with proper phantom handling, set-up, and scanning.

7.2.2 Scanner qualification

MR scanners should be identified based on their manufacturer, model, and machine name. Hardware specifications (maximum gradient strength, slew rate, etc.) should be documented. Software versions in place at the time of trial initiation, and at all upgrades should be documented as well. Local receive coils to be used should be noted, with quality checks per local institutional methods documented. Power injector

models should be noted, including date of most recent calibration.

7.2.3 Phantom imaging

To qualify the MRI scanner, a phantom imaging process is required. The QIBA DCE-MRI phantom, or a similar multi-compartment phantom with range of R_1 relaxation rate values appropriate for DCE-MRI should be utilized. With the exceptions noted below, imaging of the phantom should otherwise be performed using the same R_1 mapping ($R_1 = 1/T_1$) and DCE-MRI acquisitions that are to be used in the clinical research protocol. Coil placement should approximate that which would be used by the site for the typical patient and anatomy of interest.

7.2.4 Phantom imaging data analysis

Phantom data should be analyzed in a uniform method by a centralized DCE-MRI image analysis center. Assurance should be made by the central site that the phantom scan orientation is correct, and appropriate image rotations or inversions were performed (and documented by the image analysis center).

For all phantom image tests, a single central slice is utilized. Uniform 2 cm ROI spheres are placed within each phantom compartment, avoiding the edges of the compartments where signal intensity may be altered by Gibbs lines or other artifacts. Mean and standard deviation of the signal intensities within each ROI should be noted. There are three categories of DCE-MRI phantom data analysis: signal stability, signal linearity, and R_1 precision. In all cases, analysis should use a single central slice of the phantom data for analysis.

7.2.4.1. Signal stability

The signal stability test is performed using the DCE-MRI acquisition method to be used for the dynamic gadolinium enhanced imaging. The duration of this scan should be at least 6 minutes to test magnet stability. A single R_1 compartment with adequate SNR (10:1 or higher) is required. The mean SI in the ROI is then plotted over time. The plot should be linear and horizontal with no upward or downward trends. The root mean squared (rms) noise calculation should be similar across all aspects of the scan.

Marked deviations or drift of signal intensity over time indicate magnet instability, and should initiate a thorough evaluation of the magnet by the on-site MR physicist or site engineer prior to use in the DCE-MRI trial. The source of magnet instability should be determined and corrected prior to use in the DCE-MRI trial.

7.2.4.2 Signal linearity

In cases where signal intensity differences are to be used as a marker of tumor gadolinium concentration (see section 5), the linearity of MRI signal intensity with respect to R_1 over a range of R_1 values is required. While published guidelines on the allowed deviation from linearity do not exist, a linear correlation coefficient between SI and R_1 of 0.9 or higher is expected.

If a good linear correlation between SI and R_1 is not achieved, it is recommended that the receive coil array used for phantom imaging be evaluated to ensure that coil failure was not a cause of the abnormal results.

The phantom image may be repeated with a different local coil array, or with the body coil as receiver to further evaluate this issue.

If linearity of SI vs. R_1 is still not achieved, it is recommended that the phantom scan be repeated with a larger flip angle, in order to increase the relative T_1 weighting of the images.

7.2.4.3 R1 precision

If T_1-dependent analysis is intended for the DCE-MRI study, the fidelity of R_1 measurement should be assessed based on the phantom imaging. As uncertainty in the measurement of R_1 is an important contributor to concentration measurement bias [48], the measured phantom R_1 values based on the VFA method (see Section 5) should be compared within the known R1 values calibrated based on non-flip angle dependent methods (such as IR-prepped imaging). Simulation studies suggest that variation in the R_1 value by greater than 15% from actual may severely affect the reliability of the DCE-MRI quantification when R_1 -dependent modeling of tumor gadolinium concentration in DCE-MRI studies is used.

If accurate R_1 values cannot be reproduced, it is recommended that R_1 -dependent modeling not be performed.

7.2.5 Ongoing MRI scanner quality control

The phantom scans and analysis should be repeated at regular intervals, such as every 3 months, during the course of the study. Any changes to scanner equipment, including major hardware changes or any software version change, need to be documented and will result in the need for imaging qualification renewal prior to repeat imaging. In particular, it is strongly recommended that patients undergoing longitudinal study be scanned on the same MRI system with the same software version whenever possible. Sites performing DCE-MRI studies should be informed of planned software upgrades, and when possible such upgrades should be deferred until serial imaging of all currently enrolled patients is complete.

7.3. Quality Control of DCE-MRI studies

7.3.1 Determination of suitable tumor lesions

Patients suitable for DCE-MRI analysis must possess at least one tumor $\geq$ 2cm, well-removed from areas subject to large degrees of cardiac pulsatility artifact, that is not largely cystic or necrotic. Determination of patient eligibility is usually based on pre-enrollment imaging (often CT or clinical MRI) which then serves as a baseline study for subsequent assessments for tumor response or progression. The site radiologist then reviews these images prior to enrollment to ascertain the location of the most suitable tumor lesion(s) for analysis.

7.3.2 Selection of target lesion

Once the MRI scan commences, the radiologist or anatomic expert will review the pre-gadolinium imaging to identify putative target lesions. The DCE-MRI study then proceeds with slab placement and T_1 mapping/dynamic enhanced imaging once the target lesion is identified. Sites should strive to inspect these images to ensure absence of substantial artifacts (e.g., phase wrap, pulsatility) overlying the target

lesion, with protocol-specified adjustments to patient positioning and slab placement prior to continuing the DCE-MRI study. Once the final slab placement is confirmed, grid line overlays of the DCE-MRI slab on routine anatomic imaging (usually axial plane) is recommended to facilitate DCE-MRI slab placement on subsequent visits (e.g. by saving of a screen shot).

7.3.3 Determination of subjects unsuitable for DCE-MRI analysis

Despite best efforts and protocol adherence, on occasion, a patient enrolled and imaged in DCE-MRI study will be found to be ineligible for subsequent analysis. Reasons for eliminating patients for analysis include:

- Lack of a tumor of suitable size in the usable DCE-MRI imaging volume
- Unacceptable pulsatility, wrap, or metallic artifact involving all tumors in the usable DCE-MRI imaging volume
- All target lesions in the DCE-MRI imaging volume determined to be largely cystic or necrotic
- Patients with significant amount of ascites since anti-angiogenic therapies can be very effective at reducing ascites and, hence, altering body weight, which may substantially affect the amount of gadolinium contrast agent administered.

Determination of patient eligibility should be made by an independent reviewer who is blinded to other attributes of patient data, including (when applicable) randomization arm/drug treatment, toxicity, and clinical outcomes. Decisions on eligibility should be made on the basis of visual image assessment prior to analysis of DCE-MRI data. Quantitative criteria for defining tumors that are largely cystic or necrotic (such as percentage of pixels with enhancement above a certain threshold) should be defined in the protocol to avoid bias in decisions to eliminate patients form further DCE-MRI assessment.

7.3.4 Determination of DCE-MRI exams unsuitable for DCE-MRI analysis

In addition, individual DCE-MRI examinations may be deemed nonanalyzable based on a variety of technical deviations. These may include:

- Failure of gadolinium injection
- Gross patient motion not correctable with motion-correcting algorithms
- Failure of the imaging site to replicate the imaging parameters within acceptable standards of deviation from protocol specifications
- Failure of the imaging site to replicate anatomic DCE-MRI slab placement

Whenever possible, all anticipated instances where individual DCE-MRI data will be removed from analysis should be prespecified in the DCE-MRI protocol.

7.3.5 Editing of DCE-MRI exams prior to DCE-MRI analysis

It is recognized that DCE-MRI analysis requires post-processing of the DCE-MRI image sets. Most frequently, data sets will be subject to automated or semi-automated motion compensation schemes to eliminate or minimize the effects of image motion of subsequent DCE-MRI analysis. The methodology used for such post-processing should be documented, ideally in the DCE-MRI protocol or the standard operating procedures of the central analysis laboratory. Motion correction matrices keyed to each temporal phase

may be documented as part of the analysis routine, in order to facilitate replication of the data analysis when required.

In the course of post-processing, individual phases of the DCE-MRI exam may be found to be severely compromised by image blur or degraded by other artifacts (such as random noise spikes). Judicious selection of phases to be eliminated for analysis may be made by the central analysis team, provided that the decision to eliminate such phases is determined prior to data analysis. Elimination of baseline or early post gadolinium phases is discouraged as such post-processing may substantially alter the subsequent analysis. Data documenting these forms of post-processing should be maintained by the imaging analysis laboratory.

8. Imaging-associated Risks and Risk Management

MR safety considerations are to be established individually at each institution according to each institutions' radiology departmental guidelines and institutional review board (IRB) considerations to include policy guidelines on the following:
(1) laboratory screening for renal dysfunction prior to gadolinium-based contrast administration,
(2) contrast administration in pregnant patients and in patients who are lactating,
(3) policy on patients receiving gadolinium-based agents who have a positive history of a previous adverse event or events to iodinated or gadolinium-based contrast agents to include serious and non-serious adverse events. The American College of Radiology Manual on Contrast Media Version 7 2010 can serve as a reference guideline for each institutional policy development. This manual reflects policy statements previously released by the Food and Drug Administration (FDA) in the United States and its counterpart in the European Union, The Committee for Medicinal Products for Human Use (CHMP).

IV. Compliance

Typically clinical sites are selected due to their competence in oncology and access to a sufficiently large patient population under consideration. For DCE-MRI use as a quantitative imaging biomarker it is essential to put some effort into an imaging capability assessment prior to final site selection for a specific trial. For imaging it is important to consider the availability of:

- appropriate imaging equipment and quality control processes,
- appropriate injector equipment and contrast media,
- experienced MR technologists for the imaging procedure, and
- processes that assure imaging protocol compliant image generation at the correct point in time.

Acquisition Scanner

1.5 T MR machines with 55-70 cm bores need to be available. The scanner needs to be under quality assurance and quality control processes (including preventive maintenance schedules) appropriate for quantitative MR imaging applications, which may exceed the standard requirements for routine clinical imaging or for MR facility accreditation purposes. The scanner software version should be identified and tracked across time. It might be beneficial to identify and qualify a second scanner at the site, if available. If this is done prior to the study start there will be no difficulties later on in case the first scanner is

temporarily unavailable. Practically speaking sites are encouraged to perform longitudinal treatment trials on one instrument.

Contrast Inject Device

A power injector is required for DCE-MRI studies. It needs to be properly serviced and calibrated.

Software Analysis

When a site is performing parametric image analysis and interpretation, a DCE-MRI tool that complies with the Tofts' model should be utilized. In addition, for multi-institutional trials a central reading site is assumed.

Performing Site

MR technologists running DCE-MRI procedures should be MR-certified according to local regulations. The technologists should have prior experience in conducting dynamic contrast enhanced imaging. The person should be experienced in clinical study related imaging and should be familiar with good clinical practices (GCP). A qualified backup person is needed that should fulfill the same requirements. Contact details for both technologists should be available in case of any questions.

Imaging qualification process:

The above-mentioned details can be obtained using a simple questionnaire as a pre-qualification step. If appropriate equipment and personnel are available, a site visit is recommended. During the site visit, study related imaging protocols are discussed and, ideally, all scan parameters are entered at the MR scanner.

To qualify the scanner, a phantom imaging process is strongly recommended. The QIBA DCE-MRI phantom, or a similar multi-compartment phantom with range of relaxation rate (T_1) values appropriate for the DCE-MRI study to be performed, should be used if the Profile Claim given above is to be assured. Data should be acquired from the multi-compartment phantom using the same T_1 mapping and DCE-MRI acquisitions that will be used in the proposed clinical application or clinical research protocol (see Section 6).

The phantom scans should be repeated on a regular interval (e.g 3 months) during the course of the study. Ongoing image quality inspection on a per-scan basis is essential. Any changes to scanner equipment, including major hardware changes or any software version change, need to be documented and will result in the need for imaging qualification renewal.

Site Analysis qualification:

The data analysis procedures to be used in the DCE-MRI application should be used to analyze the T_1 mapping data and results compared to the known T_1 values of the various compartments. As uncertainty in the measurement of T_1 is an important contributor to concentration measurement bias [48], the measured values should compare within 15 % of the known values over a T_1 range of approximately 50-1000 ms. The DCE-MRI data obtained from the phantom should be analyzed to confirm the correct temporal resolution and to provide SNR measurements and signal intensity vs. T_1 characteristics for the specific DCE-MRI acquisition protocol.

Significant variations in any of these parameters during the course of an ongoing longitudinal study can affect the resulting imaging biomarker determinations, in the case of this specific claim K^{trans} and $IAUGC_{BN}$, and such changes can readily occur if there are major changes in the scanner hardware or software, e.g., an update to the pulse sequence used for the DCE-MRI and/or T_1 measurements or to the gradient subsystem. All results shall be documented and, if they pass the established acceptance values, will constitute the site qualification documentation for the DCE-MRI procedure. This process ensures study-specific training of the site personnel and needs to be documented and signed.

References

1. Tofts, P. S. et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. (1999). J Magn Reson Imaging **10**:223-232
2. Evelhoch, J. L. Key factors in the acquisition of contrast kinetic data for oncology. (1999). J Magn Reson Imaging **10**:254-259
3. Ah-See, M. L. et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. (2008). Clin Cancer Res **14**:6580-6589
4. Drevs, J. et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. (2007). J Clin Oncol **25**:3045-3054
5. Esserman, L. et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. (1999). J Clin Oncol **17**:110-119
6. Hawighorst, H. et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. (1998). Clin Cancer Res **4**:2305-2312
7. Hylton, N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. (2006). J Clin Oncol **24**:3293-3298
8. O'Connor, J. P. et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. (2007). Br J Cancer **96**:189-195
9. Rosen, M. A. and Schnall, M. D. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. (2007). Clin Cancer Res **13**:770s-776s
10. Solin, L. J. et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. (2008). J Clin Oncol **26**:386-391
11. Zahra, M. A. et al. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. (2007). Lancet Oncol **8**:63-74
12. Leach, M. O. et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. (2003). Br J Radiol **76 Spec No 1**:S87-91
13. NCI Recommendations for MR measurement methods at 1.5 Tesla and endpoints for use in Phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function. Dynamic contrast MRI (DCE-MRI) guidelines resulted from the NCI CIP MR Workshop on Translational Research in Cancer. (2004). MR Workshop on Translational Research
14. Ashton, E. et al. Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions. (2008). J Magn Reson Imaging **28**:791-796
15. Dowlati, A. et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. (2005). Clin Cancer Res **11**:7938-7944
16. Ferl, G. Z. et al. An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. (2010). Magn Reson Med **63**:1366-1375
17. Flaherty, K. T. et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. (2008). Cancer Biol Ther **7**:496-501
18. Galbraith, S. M. et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. (2002). NMR Biomed **15**:132-142
19. Liu, G. et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. (2005). J Clin Oncol **23**:5464-5473
20. Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the

pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. (2003). J Clin Oncol **21**:3955-3964
21. Ng, C. S. et al. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. (2010). AJR Am J Roentgenol **194**:W134-40
22. Padhani, A. R. et al. Reproducibility of quantitative dynamic MRI of normal human tissues. (2002). NMR Biomed **15**:143-153
23. Roberts, C. et al. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. (2006). J Magn Reson Imaging **23**:554-563
24. Stevenson, J. P. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. (2003). J Clin Oncol **21**:4428-4438
25. Wedam, S. B. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. (2006). J Clin Oncol **24**:769-777
26. Zweifel, M. and Padhani, A. R. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? (2010). Eur J Nucl Med Mol Imaging **37 Suppl 1**:S164-82
27. Wang, Y., Spiller, M. and Caravan, P. Evidence for weak protein binding of commercial extracellular gadolinium contrast agents. (2010). Magn Reson Med **63**:609-616
28. Ledermann, H. P. et al. Screening for renal insufficiency following ESUR (European Society of Urogenital Radiology) guidelines with on-site creatinine measurements in an outpatient setting. (2010). Eur Radiol **20**:1926-1933
29. Lee, Y. J. et al. Suboptimal contrast-enhanced carotid MR angiography from the left brachiocephalic venous stasis. (1999). J Magn Reson Imaging **10**:503-509
30. Tseng, Y. C. et al. Venous reflux on carotid computed tomography angiography: relationship with left-arm injection. (2007). J Comput Assist Tomogr **31**:360-364
31. You, S. Y. et al. Effects of right- versus left-arm injections of contrast material on computed tomography of the head and neck. (2007). J Comput Assist Tomogr **31**:677-681
32. B, H. and B, S. Determining optical flow. (1981). Artificial intelligence
33. Sharp, G. C. et al. GPU-based streaming architectures for fast cone-beam CT image reconstruction and demons deformable registration. (2007). Phys Med Biol **52**:5771-5783
34. Pluim, J. P., Maintz, J. B. and Viergever, M. A. Mutual-information-based registration of medical images: a survey. (2003). IEEE Trans Med Imaging **22**:986-1004
35. Parker, G. J. et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. (1997). J Magn Reson Imaging **7**:564-574
36. Vonken, E. J. et al. Measurement of cerebral perfusion with dual-echo multi-slice quantitative dynamic susceptibility contrast MRI. (1999). J Magn Reson Imaging **10**:109-117
37. Ashton, E., McShane, T. and Evelhoch, J. Inter-operator variability in perfusion assessment of tumors in MRI using automated AIF detection. (2005). Med Image Comput Comput Assist Interv **8**:451-458
38. Rijpkema, M. et al. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. (2001). J Magn Reson Imaging **14**:457-463
39. Tofts, P. S. and Kermode, A. G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. (1991). Magn Reson Med **17**:357-367
40. E, A. System and method for Identifying Optimized Blood Signal in Medical Images to Eliminate Flow Artifacts. (2007).
41. McGrath, D. M. et al. Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. (2009). Magn Reson Med **61**:1173-1184
42. Meng, R. et al. Comparison between population average and experimentally measured arterial input function in predicting biopsy results in prostate cancer. (2010). Acad Radiol **17**:520-525

43. Parker, G. J. et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. (2006). Magn Reson Med **56**:993-1000
44. Wang, Y. et al. Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. (2008). Magn Reson Med **59**:1183-1189
45. Mouridsen K et al. Subject-specific AIF optimizes reproducibility of perfusion parameters in longitudinal DSC-MRI in comparison to session and population level AIF. (2011). International Society of Magnetic Resonance in Medicine
46. S, K. Peripheral blood flow measurement. (1960). Methods in Medical research **8**
47. Ahearn, T. S. et al. The use of the Levenberg-Marquardt curve-fitting algorithm in pharmacokinetic modelling of DCE-MRI data. (2005). Phys Med Biol **50**:N85-92
48. Schabel, M. C. and Parker, D. L. Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. (2008). Phys Med Biol **53**:2345-2373
49. Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. (1982). Am J Clin Oncol **5**:649-655

Appendices

Appendix A: Acknowledgements and Attributions

I. Executive Summary	*Jeffrey Evelhoch*
II. Clinical Context and Claims	*Mitchell Schnall*
III. Profile Details	
1. *Subject Handling*	*Alex Guimaraes*
2. *Imaging Procedure*	*Ed Jackson/Sandeep Gupta*
3. *Image Post-processing*	*Sandeep Gupta*
4. *Parametric image formation*	*Ed Ashton*
5. *Parametric image analysis*	*Dan Barboriak*
6. *Archiving and Distribution of Data*	*Sandeep Gupta*
7. *Quality Control*	*Mark Rosen*
8. *Imaging associated Risks and Risk Management*	*Orest Boyko*

Appendix B: Conventions and Definitions

B.1 List of Abbreviations

- VIF: Vascular input function
- DCE-MRI: Dynamic contrast enhanced magnetic resonance imaging
- ECOG: Eastern Cooperative Oncology Group
- eGFR: estimated Glomerular Filtration Rate
- Gd-DTPA: Gadolinium – diethylene triamine pentaacetic acid
- IAUGCBN: Initial area under the Gadolinium concentration blood normalized
- Ktrans: Permeability transfer constant
- QIBA: Quantitative Imaging Biomarkers Alliance
- ROI: Region of Interest
- VEGF: Vascular Endothelial Growth Factor
- VFA: Variable Flip angle
- GCP: Good Clinical Practice
- SPGR (Spoiled Gradient Recalled)

B.2 ECOG Performance Status Descriptions, by grade: [49]

0: Fully active, able to carry on all pre-disease performance without restriction
1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light-house work, office work
2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5: Dead

Appendix C: Spreadsheet on reproducibility data

Reference	Year	Field Strength (T)	Organ System	N	Contrast Agent	Injection Rate	Flush	Temporal Resolution (s) / # sections
Ng, Raunig, Jackson, et al	2010	1.5	Liver / Lung	12 (lung) / 11 (liver)	Magnevist (0.1 mmol/kg)	3 ml/s	20 ml saline @ 3 ml/s	10.4 / 10
Ferl, Lu, Friesenhahn, et al	2010	1.5	Brain (GBM)	16	Magnevist (0.1 mmol/kg)	3 ml/s	Not stated	4.8 / 16
Ashton, Raunig, Ng, et al	2008	1.5	Liver / Lung	12 (lung) / 12 (liver)	Magnevist (0.1 mmol/kg)	3 ml/s	20 ml saline @ 3 ml/s	10.4 / 10
Lankester, Taylor, Stirling, et al	2007	1.5	Various tumors (pelvic)	20	Magnevist (0.1 mmol/kg)	4 ml/s	Not stated	12.0 / 4
Roberts, Issa, Stone, et al	2006	1.5	Brain and Abdomen	4 (brain) / 9 (abdo)	Omniscan (brain); Magnevist (abdo); 0.1 mmol/kg	Hand injected (3-4 s)	Brain: same volume; Abdo: not stated	8s / 25 (brain); 8 s early and 75 s late (abdo)
Morgan, Utting, Higginson, et al	2006	1.5	Various tumors (liver, lung, lymph node)	10	Magnevist or Omniscan (0.1 mmol/kg) or	Manually, less then 5 s	Not stated	0.5 / 1
Lankester, Taylor, Stirling, et al	2005	1.5	Various tumors (body)	20	Magnevist (0.1 mmol/kg)	4 ml/s	Not stated	Not stated
Jackson, Jayson, Li, et al.	2003	1.5	Brain (glioma)	9	Omniscan (0.1 mmol/kg)	Hand injected (3-4 s)	Saline at same volume and injection duration	5.1 - 8.7 / 24
Galbraith, Lodge, Taylor et al	2002	1.5	Various tumors (body)	16	Magnevist (0.1 mmol/kg)	Not stated	Not stated	11.9
Rijpkema, Kaanders, Joosten et al	2001	1.5	Various (6 H&N; 2 brain; 3 prostate)	11	Magnevist (15 ml)	2.5 ml/s	Not stated	2

Model (Tofts, GKM, etc)	Whole ROI or Pixelwise?	Parameters Reported	AIF	T1 Correction?	If yes, T1 mapping technique?	Fitted Data Type (Δ[Gd], ΔSI, ΔSI/S0)
2 param GKM	Pixel	Ktrans, kep, $IAUC90_{BN}$	Yes, automated	No		SI
Deconvolution and 3-param GKM	Pixel	Ktrans, ve	Yes (venous)	Yes	VFA (5, 10, 15, 20, 25, 30)	[Gd]
2 param GKM	Pixel	Ktrans, kep, $IAUC90_{BN}$	Yes, automated	No		SI
IAUGC, Kety (=Tofts?)	Pixel	IAUGC60, Ktrans, kep, Ve	No (pooled data)	Yes	Proton density reference	[Gd]
IAUC, Tofts (2 param), Tofts (3 param)	Pixel	IAUC60 (Model 1); Ktrans, ve (Model 2); Ktrans, ve, vp (Model 3)	No (Model based)	Yes	VFA (2, 20, 35: brain; 2, 13, 28: abdo)	[Gd]
IAUC, Tofts (2 compart)	Not specified	PE, IAUC60, IAUC180, Ktrans	Yes and No, local data, and modified on published data	Yes?	IR	
IAUC, Tofts (2 param)	Pixel	IAUCGC60, Ktrans	No (Model based)	Yes	Proton density reference	[Gd]
2 param GKM	Pixel	Ktrans, ve	Yes (sagittal sinus, fitted to biexponential)	Yes	VFA (2, 10, 35)	[Gd]
IAUC, Tofts (2 param)	Pixel	IAUC90, Ktrans, kep, ve	No (Model based)	Yes	Proton density reference	[Gd]
3 param GKM	Pixel	kep	Yes	Yes	Proton density reference	[Gd]

1144
1145

Motion Correction?	Primary Findings (test/retest CV, CI, etc)	Additional Findings	Reference
Yes	Within Patient CV. Ktrans: liver:8.9%, lung:17.9%; IAUC: liver:9.9%, lung:18.2%.	Sample size requirements of liver and lung for %change in Ktrans and IAUC	Ng, Raunig, Jackson, et al
None stated	Repeat baseline CV%. Ktrans: 13.6%, ve: 23.6%	Deconvolution method: AUC/MRT: 10.7%, AUC: 12.7%	Ferl, Lu, Friesenhahn, et al
Yes	Within Patient CV. Ktrans: liver:10.6%, lung:19.3%; IAUC: liver:9.8%, lung:15.7%.	Also used Tofts model derived method; Within Patient CV (Ktrans, kep). Ktrans: liver:35.6%, lung:20.7%; IAUC: liver:33.1%, lung:18.9%.	Ashton, Raunig, Ng, et al
None stated	Within Patient CV. Ktrans: 20.3%, Ve: 8.3%, kep: 17.4%, IAUGC: 12.1%	Additional results to previous paper of 2005	Lankester, Taylor, Stirling, et al
None stated	RMS CV%. IAUC60: 19%; Model 2: Ktrans:13%, ve:11%; Model 3: Ktrans:19%, ve:14%, vp:30%	Ktrans vs IAUC60 correlation	Roberts, Issa, Stone, et al
Yes	Within Patient CV. Ktrans: 19.1%, IAUC60: 15.8%, IAUC180: 16.1%, PE: 15.9%	Correlation of IAUC60 and IAUC180 with Ktrans after treatment	Morgan, Utting, Higginson, et al
None stated	Within Patient CV. Ktrans: 20.3%, IAUGC: 12.1%		Lankester, Taylor, Stirling, et al
None stated	Within Patient CV. Ktrans: 7.7%; ve: 6.2%	Max intensity change / unit time (MITR): 17.9%; Time to 90% enhancement (T90): 7.1%; Tumor volume: 4.0%; Native tumor T1 relaxation rate ($R_{1,0}$): 9.2%	Jackson, Jayson, Li, et al.
None stated	Within Patient CV. Ktrans: 24%, kep: 21%, ve: 8.5%, IAUC90:12%	Muscle data (whole ROI only); Whole ROI tumor data	Galbraith, Lodge, Taylor et al
None stated	No statistical difference in kep in 10 of 11 patients (Student's t-test, p:0.05)		Rijpkema, Kaanders, Joosten et al

Appendix D: Model-specific Instructions and Parameters

The presence of specific product models/versions in the following tables should not be taken to imply that those products are fully compliant with the QIBA Profile. Compliance with a profile involves meeting a variety of requirements of which operating by these parameters is just one. To determine if a product (and a specific model/version of that product) is compliant, please refer to the QIBA Conformance Document for that product. G.1. Image Acquisition Parameters The following technique tables list acquisition parameter values for specific models/versions that can be expected to produce data meeting the requirements of Section 7.1.

These technique tables may have been prepared by the submitter of this imaging protocol document, the clinical trial organizer, the vendor of the equipment, and/or some other source. (Consequently, a given model/version may appear in more than one table.) The source is listed at the top of each table.

Sites using models listed here are encouraged to consider using these parameters for both simplicity and consistency. Sites using models not listed here may be able to devise their own acquisition parameters that result in data meeting the requirements of Section 7.1 and conform to the considerations in Section 13.

In some cases, parameter sets may be available as an electronic file for direct implementation on the imaging platform.

parameter	value	notes
Routine tab		
slabs	1	
distance factor	irrevelant	
position	as needed	
orientation	coronal	
phase enc. dir.	R >> L	
rotation	0.0 deg	
phase oversampling	0%	
slice oversampling	0%	
slices per slab	26	Reconstructed images, interpolated by zero-filling. The slab thickness is 4.25 x 26 = 110.5 mm
FoV read	400	
FoV phase	81.3%	325 mm
slice thickness	4.25 mm	For 3-D, this is the slice *spacing*. The true slice thickness is this number divided by the slice resolution, in this case 4.25 / 0.62 = 6.85 mm.
TR	5.03 ms	
TE	1.9 ms	
averages	1	NEX
concatenations	1	
filter	none	
coil elements	as needed	
Contrast tab		
flip angle	30 deg	

fat suppression	none	
water supp.	none	
Dixon	no	
save original images	on	
averaging mode	short term	
reconstruction	magnitude	
measurements	40	
measurement series	each measurement	
pause after measurement	0 sec	
Resolution tab		
base resolution	256	readout pixel size 1.56 mm
phase resolution	62%	phase pixel size 2.52 mm
slice resolution	62%	Controls zero-filling in slice. If no partial Fourier processing is used, 16 partitions are acquired. The raw matrix is padded with 10 zeros to reconstruct 26 slices: 16 / 0.62 = 26. Divide the slice spacing by the slice resolution to get the slice thickness: 4.25 / 0.62 = 6.85 mm
phase partial Fourier	choose 7/8ths here or below (slice)	If 7/8ths is chosen, partial Fourier processing is used to reduce the number of acquired lines to: 256 x 0.62 x 0.813 x 7/8 = 113
slice partial Fourier	choose 7/8ths here or above (phase)	If 7/8ths is chosen, 14 partitions are acquired to provide the data for 16. Ten additional zeros are added to reconstruct 26 slices.
interpolation	on	In-plane zero-filling to 512 x 512.
PAT mode	none	No SENSE or GRAPPA
matrix coil mode	as needed	
image filter	off	
distortion correction	off	also called “large FoV filter”
prescan normalize	off	
normalize	off	Acts on individual slices, so must be turned off.
raw filter	off	
elliptical filter	off	

Geometry card		
multi-slice mode	irrelevant	
series	irrelevant	
special sat.	none	
(remainder)		May be ignored.
System Card		
shim mode	standard	
save uncombined	off	
adjust with body coil	off	
Physio card		
1st signal/mode	none	
rsp. control	off	
Inline card		
3D centric reordering	off	
(remainder)	off	
Sequence card		
introduction	off	
dimension	3D	
elliptical scanning	off	
asymmetric echo	allowed, weak	
contrasts	1	
bandwidth	250 Hz/pixel	Corresponds to ± 32 KHz.

optimization	min TE	
RF pulse type	normal	
gradient mode	fast	
excitation	slab-sel.	
RF spoiling	on	For the FLASH sequence.
Tool Tips		Roll the cursor over the appropriate item to view these.
readout echo position	38%	Roll over "echo asymmetry."
matrix size	129 x 256	Roll over "phase resolution." This size includes the effects of reduced pixel resolution and rectangular FoV.
slab thickness	110 mm	
pulse sequence	fl3d_vibe	Roll over the pulse sequence abbreviation.

SNR protocol: change measurements to 8 and flip angle to 15º.

Variable flip angle protocol for T_1: one measurement, 4 averages, and flip angles of 2º, 5º, 10º, 15º, 20º, 25º, and 30º.

QIBA DCE-MRI Abdominal Protocol for VB15, VB17, and VD11 Software

These are the 400 Hz/pixel protocols.

parameter	value	notes
Routine tab		
slabs	1	
distance factor	irrelevant	
position	as needed	
orientation	coronal	
phase enc. dir.	R >> L	
rotation	0.0 deg	
phase oversampling	0%	
slice oversampling	0%	
slices per slab	26	Reconstructed images, interpolated by zero-filling. The slab thickness is 4.25 x 26 = 110.5 mm
FoV read	400	
FoV phase	81.3%	325 mm
slice thickness	4.25 mm	For 3-D, this is the slice *spacing*. The true slice thickness is this number divided by the slice resolution, in this case, 4.25 / 0.62 = 6.85 mm.
TR	3.61 ms 3.91 ms 4.76 ms	VD11, Aera VB17, Espree VB15B, Verio
TE	1.49 ms 1.48 ms 1.43 ms	VD11, Aera VB17, Espree VB15B, Verio
averages	1	NEX
concatenations	1	
filter	none	
coil elements	as needed	
Contrast tab		

flip angle	30 deg	
fat suppression	none	
water suppression	none	
Dixon	no	
save original images	on	
averaging mode	short term	
reconstruction	magnitude	
measurements	50	as needed
measurement series	each measurement	
pause after measurement	0 sec	for all measurements
Resolution tab		
base resolution	256	readout pixel size 1.56 mm
phase resolution	62%	phase pixel size 2.52 mm
slice resolution	62%	Controls zero-filling in slice. Sixteen partitions are acquired. The raw matrix is padded with 10 zeros to reconstruct 26 slices: 16 / 0.62 = 26 Divide the slice spacing by the slice resolution to get the slice thickness: 4.25 / 0.62 = 6.85 mm
phase partial Fourier	off	No further reduction in the number of acquired lines: 256 x 0.62 x 0.813 = 129
slice partial Fourier	off	No further reduction in the number of acquired partitions (16).
interpolation	on	In-plane zero-filling to 512 x 512.
PAT mode	none	No SENSE or GRAPPA
matrix coil mode	as needed	
image filter	off	
distortion correction	off	
prescan normalize	off	
normalize	off	Acts on individual slices, so must be turned off.
$\mathbf{B}_1$ filter	off	
raw filter	off	
elliptical filter	off	

POCS	off	
Geometry card		
multi-slice mode	irrelevant	
series	irrelevant	
special sat.	none	
Set-n-Go Protocol	off	
inline composing	off	
System Card		
shim mode	tune up	
save uncombined	off	
adjust with body coil	off	
confirm freq. adjustment	off	
Physio card		
1st signal/mode	none	
resp. control	off	
Inline card		
3D centric reordering	off	
(remainder)	off	
Sequence card		
introduction	off	
dimension	3D	
elliptical scanning	off	

asymmetric echo	allowed, weak	
contrasts	1	
bandwidth	400 Hz/pixel	Corresponds to ± 51.2 KHz.
optimization	min TE	
RF pulse type	normal	
gradient mode	fast normal fast	VD11, Aera VB17, Espree VB15B, Verio
excitation	slab-sel.	
RF spoiling	on	For the FLASH sequence.
Tool Tips		Roll the cursor over the appropriate item to view these.
readout echo position	38%	Roll over "echo asymmetry."
matrix size	129 x 256	Roll over "phase resolution." This size includes the effects of reduced pixel resolution and rectangular FoV.
slab thickness	110 mm	
pulse sequence	fl3d_vibe	Roll over the pulse sequence abbreviation.

SNR protocol: change measurements to 8 and flip angle to 15º.

Variable flip angle protocol for T_1: one measurement, 4 averages, and flip angles of 2º, 5º, 10º, 15º, 20º, 25º, and 30º.

GE

GE Scanners	
DCE Scan	
B0:	1.5T
Grad Subsystem:	BRM, TRM (Zoom), CRM, XRM
Coil:	Torso Phased Array
Sequence:	3D FSPGR
Slice orientation:	Oblique Coronal
Imaging Options:	EDR, MPH, ZIP2, ZIP512
User CVs:	Turbo[1]=2 / Slice res=100%
TE (ms):	0.9
TR (ms):	4.1[2]
Flip Angle (deg):	30
Bandwidth:	+/- 32 kHz
NEX:	1
FOV (cm):	40
Phase FOV:	0.8
Slice Thickness (mm):	5
# locs per slab:	16
Acquisition matrix:	256 x 160
Freq Direction:	S/I
Scan time/volume:	8.5[2] sec
Scan time / 40 volumes:	5:40[2] min
T1 Mapping Protocol	
B0:	1.5T
Grad Subsystem:	BRM, TRM (Zoom), CRM, XRM
Coil:	Torso Phased Array
Sequence:	3D FSPGR
Slice orientation:	Oblique Coronal
Imaging Options:	EDR, MPH, ZIP2, ZIP512
User CVs:	Turbo[1]=0 / Slice res=100%
TE (ms):	1.0
TR (ms):	5.2[2]
Flip Angle (deg):	2, 5, 10, 15, 20, 25, 30
Bandwidth:	+/- 32 kHz
NEX:	4
FOV (cm):	40
Phase FOV:	0.8
Slice Thickness (mm):	5
# locs per slab:	16
Acquisition matrix:	256 x 160
Freq Direction:	S/I
Acq Time (min):	43[2] sec / flip angle

Notes:

1. Turbo (User CV or Advanced) should be set to 2 (fastest) for the DCE scan, but should be set to 0 (slowest) for the T1 mapping scans. If Turbo is set to 2 for the T1 mapping scans, the value of TE will change with flip angle, particularly for larger flip angle values.
2. The value of TR and, therefore, the scan time/volume and total scan time, will change slightly depending on the particular gradient subsystem used for the scans. The values above were obtained on a CRM platform and similar or slightly longer values can be obtained on BRM platforms, TRM platforms (if in Zoom Mode; substantially longer TR values are obtained if in Whole Mode), and XRM platforms.

Phillips

INFO PAGE	
Total scan duration	05:50.3
Rel. signal level (%)	100
Act. TR/TE (ms)	5.0 / 2.4
Dyn. scan time	00:08.3
Time to k0	00:01.9
ACQ matrix M x P	256 x 162
ACQ voxel MPS (mm)	1.64 / 2.10 / 4.00
REC voxel MPS (mm)	0.82 / 0.82 / 2.00
Scan percentage (%)	78.125
Act. WFS (pix) / BW (Hz)	0.692 / 313.8
Min. WFS (pix) / Max. BW (Hz)	0.148 / 1464.8
SAR / whole body	< 40 % / 1.6 W/kg
Whole body / level	< 1.6 W/kg / normal
B1 rms [uT]	2.865556
PNS / level	44 % / normal
Sound Pressure Level (dB)	20.09241
MOTION	
Cardiac synchronization	no
Respiratory compensation	no
Navigator respiratory comp	no
Flow compensation	no
fMRI echo stabilisation	no
NSA	2
SMART	yes
DYN/ANG	
Angio / Contrast enh.	contrast enh.
Quantitative flow	no
CE profile order	linear
Manual start	no
Dynamic study	individual
dyn scans	42
recon multiplier	1
dyn scan times	user defined
(mm:ss)	shortest (00:00.0), shortest (00:08.4), shortest (00:16.7), shortest (00:25.0), shortest (00:33.4), manual (00:41.7), shortest (00:50.1), shortest (00:58.4), shortest (01:06.8), shortest (01:15.1), shortest (01:23.4), shortest (01:31.8), shortest (01:40.1), shortest (01:48.5), shortest (01:56.8)

GEOMETRY	
Nucleus	H1
Coil selection	SENSE-XL-Torso
element selection	All
connection	d
Dual coil	no
CLEAR	no
FOV FH (mm)	420
RL (mm)	341.25
AP (mm)	48
Voxel size FH (mm)	1.64
RL (mm)	2.1
AP (mm)	2
Recon voxel size (mm)	0.8203125
Fold-over suppression	yes
Slice oversampling	user defined
oversample factor	1
Reconstruction matrix	512
SENSE	no
k-t BLAST	no
Overcontiguous slices	yes
Stacks	1
slices	24
slice orientation	coronal
fold-over direction	RL
fat shift direction	F
Chunks	1
PlanAlign	no
REST slabs	0
Catheter tracking	no
Interactive positioning	no
Allow table movement	no
OFFC/ANG	
Stacks	1
Stack Offc. AP (P=+mm)	0
RL (L=+mm)	0
FH (H=+mm)	0
Ang. AP (deg)	0
RL (deg)	0
FH (deg)	0
Shim Size AP (mm)	100
RL (mm)	100
FH (mm)	100
Offc. AP (P=+mm)	0
RL (L=+mm)	0
FH (H=+mm)	0
Ang. AP (deg)	0

CONTRAST	
Scan type	Imaging
Scan mode	3D
technique	FFE
Contrast enhancement	T1
Acquisition mode	cartesian
Fast Imaging mode	none
3D non-selective	no
Echoes	1
partial echo	no
shifted echo	no
TE	shortest
Flip angle (deg)	30
TR	shortest
Halfscan	yes
factor Y	0.65
factor Z	0.85
Water-fat shift	maximum
Shim	volume
ShimAlign	no
Fat suppression	no
Water suppression	no
MTC	no
Research prepulse	no
Diffusion mode	no
Elastography mode	no
SAR mode	high
B1 mode	default
PNS mode	high
Gradient mode	maximum
SofTone mode	no

	shortest (01:48.5), shortest (01:56.8), shortest (02:05.1), shortest (02:13.5), shortest (02:21.8), shortest (02:30.2), shortest (02:38.5), shortest (02:46.8), shortest (02:55.2), shortest (03:03.5), shortest (03:11.9), shortest (03:20.2), shortest (03:28.5), shortest (03:36.9), shortest (03:45.2), shortest (03:53.6), shortest (04:01.9), shortest (04:10.2), shortest (04:18.6), shortest (04:26.9), shortest (04:35.3), shortest (04:43.6), shortest (04:51.9), shortest (05:00.3), shortest (05:08.6), shortest (05:17.0), shortest (05:25.3), shortest (05:33.6), shortest (05:42.0),
dummy scans	0
immediate subtraction	no
fast next scan	no
synch. ext. device	no
prospect. motion corr.	no
Keyhole	no
Arterial Spin labeling	no
POST/PROC	
Preparation phases	auto
Manual Offset Freq.	no
SmartPlan survey	no
B0 field map/Dixon	no
B1 field map	no
MIP/MPR	no
Images	M, no, no, no
Autoview image	M
Calculated images	no, no, no, no
Reference tissue	Liver
Preset window contrast	soft
Reconstruction mode	real time
reuse memory	no
Save raw data	no
Hardcopy protocol	no

[illegible]	[illegible]
Ang. AP (deg)	0
RL (deg)	0
FH (deg)	0